Policy Changes Announced by Trump Administration Affecting Vaccination Tracking

As 2026 begins, there are some noteworthy policy updates from the Trump administration regarding the Centers for Medicare and Medicaid Services (CMS). These changes aim to alleviate the federal emphasis on tracking vaccination rates. They also intend to lessen the pressure on health providers, reducing their incentive to maintain high vaccination compliance through quality tracking and reporting.

“Government bureaucracies should not force doctors and families to accept vaccines or penalize doctors who respect patients’ choices. That is over. Under the Trump administration, HHS will protect informed consent, respect religious freedom, and protect medical freedom,” noted Secretary Kennedy recently.

Despite these announcements, immunization registration and surveillance systems remain operational. Health care providers still have the opportunity to report vaccination data through various avenues. The changes specifically aim to reduce the tracking and reporting mandates at the state level for Medicaid and CHIP populations, which lessens the indirect pressure on physicians working with these patients.

While the data system overhaul hasn’t been completed, the administration has done away with previous financial requirements that compelled states and healthcare providers to meet particular quotas.

This week, a letter from the State Health Department (SHO #25-005) confirmed updates to the quality standards for the Medicaid and CHIP programs for 2026 and 2027. Notably, four immunization-related measures have been eliminated from the mandatory requirements:

• Childhood Immunization Status (CIS-CH)
• Immunization for Youth (IMA-CH)
• Prenatal immunization status: <21 years of age (PRS-CH)
• Prenatal immunization status: 21 years and older (PRS-AD)

These measures will now be reported voluntarily by states, with CMS clarifying that there are no more federal payments or penalties tied to immunization performance in Medicaid or CHIP.

It’s important to remember that while both Medicaid and CHIP provide behavioral health services, Medicaid serves a broader demographic, including adults and people with disabilities, whereas CHIP focuses primarily on children and some pregnant women in middle-income families.

Additionally, the agency has advised states, particularly those with Democratic leadership, against utilizing these measures in their value-based purchasing initiatives. States like California and New York implement such programs to incentivize providers based on selected health objectives, which contrasts with a more autonomy-driven clinical judgment.

CMS also expressed intentions to collaborate with various stakeholders to create new vaccination strategies that more effectively respect patient choices, discuss vaccine safety, and consider religious exemptions.

In a separate update for the 2026 Medicare Physician Fee Schedule, one vaccination-related quality measure, Quality ID #508 (Adult COVID-19 Vaccination Status), has been removed from the Performance-Based Incentive Payment System (MIPS). This measure, which tracked adult COVID-19 vaccination rates, will no longer affect MIPS quality scores. Providers are also now allowed to document patient refusals for various reasons, ensuring those decisions won’t negatively impact their scores.

The changes align with the broader initiatives under the Trump administration, particularly the “Make America Healthy Again” (MAHA) campaign, championed by HHS Secretary Robert F. Kennedy Jr. This campaign promotes personal health choices while curtailing mandatory federal directives.

Dr. Mehmet Oz, a prominent figure in the MAHA movement, oversees essential aspects of this initiative. While RFK Jr. focuses on food and drug science, Dr. Oz’s role includes addressing necessary policy changes related to health and nutrition funding through government channels.

While officials describe these updates as a move toward increased medical independence, CMS positions the changes as enhancements to quality measures in line with shifting public health needs.

Importantly, the 2026 rules do maintain vaccine coverage. Under the One Big Beautiful Bill Act (OBBBA), all vaccines recommended by the CDC will still be available to Medicare beneficiaries at no out-of-pocket expense. The administration’s hope seems to be to foster a trusting relationship between doctors and patients by removing financial pressures and facilitating individualized care instead of rigid mandates.

It’s worth noting that the pharmaceutical industry is incredibly influential, often reflecting their power in unprecedented lobbying expenditures of late. In late 2025 and early 2026, spending from this sector hit historic levels, largely in defense of the Trump administration’s health policy shifts. For instance, in the first half of 2025, the industry spent an astonishing $227 million on federal lobbying.

Public reactions to these changes have been varied. Some users on social media shared their experiences and frustrations regarding vaccination practices, emphasizing how difficult it has been for them to secure medical care for unvaccinated children in the past.